Cargando…

Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis

BACKGROUND: It is still unknown what is the appropriate time between neoadjuvant chemotherapy (NACT) and gastrectomy in cases of gastric cancer. To comprehend the relationship more clearly between waiting time after NACT before having a gastrectomy and survival results, a meta-analysis was done. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Naveed, Shah, Banday, Saquib Zaffar, Qari, Hasina, Zahoor, Sheikh, Batoo, Azhar Jan, Wahid, Mir Abdul, Haq, Mohd Fazl Ul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028703/
https://www.ncbi.nlm.nih.gov/pubmed/36959991
http://dx.doi.org/10.5005/jp-journals-10018-1382
_version_ 1784910003947175936
author Naveed, Shah
Banday, Saquib Zaffar
Qari, Hasina
Zahoor, Sheikh
Batoo, Azhar Jan
Wahid, Mir Abdul
Haq, Mohd Fazl Ul
author_facet Naveed, Shah
Banday, Saquib Zaffar
Qari, Hasina
Zahoor, Sheikh
Batoo, Azhar Jan
Wahid, Mir Abdul
Haq, Mohd Fazl Ul
author_sort Naveed, Shah
collection PubMed
description BACKGROUND: It is still unknown what is the appropriate time between neoadjuvant chemotherapy (NACT) and gastrectomy in cases of gastric cancer. To comprehend the relationship more clearly between waiting time after NACT before having a gastrectomy and survival results, a meta-analysis was done. METHODS: Retrospective and prospective research from the PubMed, Embase, and Cochrane Library databases were thoroughly reviewed. Research examining the impact of delays of 4, 4–6, and above 6 weeks between the conclusion of NACT and surgery in patients with locally advanced gastric cancer qualified as eligible studies. The pathologic complete response (pCR) rate served as the main outcome indicator. Additional outcome metrics were overall survival (OS) and survival free of illness. RESULTS: The meta-analysis showed that patients with locally advanced gastric cancer with a waiting time for surgery of above 4 weeks compared to those with a waiting time for surgery of below 4 weeks saw a significantly higher pCR rate (pCR) [odds ratio (OR): 1.67; 95% confidence interval (CI): 1.07–2.60; p = 0.02]. The meta-analysis found no appreciable OS differences [hazard ratio (HR): 0.93; 95% CI: 0.76–1.13; p = 0.44). CONCLUSIONS: Time to surgery (TTS) had no effect on the survival results, according to our data. Only in the group where delaying surgery by more than 4 weeks after the end of NACT improved pathological response, but had no effect on survival. HOW TO CITE THIS ARTICLE: Naveed S, Banday SZ, Qari H, et al. Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis. Euroasian J Hepato-Gastroenterol 2022;12(2):81–91.
format Online
Article
Text
id pubmed-10028703
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Jaypee Brothers Medical Publishers
record_format MEDLINE/PubMed
spelling pubmed-100287032023-03-22 Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis Naveed, Shah Banday, Saquib Zaffar Qari, Hasina Zahoor, Sheikh Batoo, Azhar Jan Wahid, Mir Abdul Haq, Mohd Fazl Ul Euroasian J Hepatogastroenterol Research Article BACKGROUND: It is still unknown what is the appropriate time between neoadjuvant chemotherapy (NACT) and gastrectomy in cases of gastric cancer. To comprehend the relationship more clearly between waiting time after NACT before having a gastrectomy and survival results, a meta-analysis was done. METHODS: Retrospective and prospective research from the PubMed, Embase, and Cochrane Library databases were thoroughly reviewed. Research examining the impact of delays of 4, 4–6, and above 6 weeks between the conclusion of NACT and surgery in patients with locally advanced gastric cancer qualified as eligible studies. The pathologic complete response (pCR) rate served as the main outcome indicator. Additional outcome metrics were overall survival (OS) and survival free of illness. RESULTS: The meta-analysis showed that patients with locally advanced gastric cancer with a waiting time for surgery of above 4 weeks compared to those with a waiting time for surgery of below 4 weeks saw a significantly higher pCR rate (pCR) [odds ratio (OR): 1.67; 95% confidence interval (CI): 1.07–2.60; p = 0.02]. The meta-analysis found no appreciable OS differences [hazard ratio (HR): 0.93; 95% CI: 0.76–1.13; p = 0.44). CONCLUSIONS: Time to surgery (TTS) had no effect on the survival results, according to our data. Only in the group where delaying surgery by more than 4 weeks after the end of NACT improved pathological response, but had no effect on survival. HOW TO CITE THIS ARTICLE: Naveed S, Banday SZ, Qari H, et al. Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis. Euroasian J Hepato-Gastroenterol 2022;12(2):81–91. Jaypee Brothers Medical Publishers 2022 /pmc/articles/PMC10028703/ /pubmed/36959991 http://dx.doi.org/10.5005/jp-journals-10018-1382 Text en Copyright © 2022; The Author(s). https://creativecommons.org/licenses/by-nc/4.0/© The Author(s). 2022 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Naveed, Shah
Banday, Saquib Zaffar
Qari, Hasina
Zahoor, Sheikh
Batoo, Azhar Jan
Wahid, Mir Abdul
Haq, Mohd Fazl Ul
Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis
title Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis
title_full Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis
title_fullStr Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis
title_full_unstemmed Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis
title_short Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis
title_sort impact of the interval between neoadjuvant chemotherapy and gastrectomy on pathological response and survival outcomes for patients with locally advanced gastric cancer: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028703/
https://www.ncbi.nlm.nih.gov/pubmed/36959991
http://dx.doi.org/10.5005/jp-journals-10018-1382
work_keys_str_mv AT naveedshah impactoftheintervalbetweenneoadjuvantchemotherapyandgastrectomyonpathologicalresponseandsurvivaloutcomesforpatientswithlocallyadvancedgastriccancerametaanalysis
AT bandaysaquibzaffar impactoftheintervalbetweenneoadjuvantchemotherapyandgastrectomyonpathologicalresponseandsurvivaloutcomesforpatientswithlocallyadvancedgastriccancerametaanalysis
AT qarihasina impactoftheintervalbetweenneoadjuvantchemotherapyandgastrectomyonpathologicalresponseandsurvivaloutcomesforpatientswithlocallyadvancedgastriccancerametaanalysis
AT zahoorsheikh impactoftheintervalbetweenneoadjuvantchemotherapyandgastrectomyonpathologicalresponseandsurvivaloutcomesforpatientswithlocallyadvancedgastriccancerametaanalysis
AT batooazharjan impactoftheintervalbetweenneoadjuvantchemotherapyandgastrectomyonpathologicalresponseandsurvivaloutcomesforpatientswithlocallyadvancedgastriccancerametaanalysis
AT wahidmirabdul impactoftheintervalbetweenneoadjuvantchemotherapyandgastrectomyonpathologicalresponseandsurvivaloutcomesforpatientswithlocallyadvancedgastriccancerametaanalysis
AT haqmohdfazlul impactoftheintervalbetweenneoadjuvantchemotherapyandgastrectomyonpathologicalresponseandsurvivaloutcomesforpatientswithlocallyadvancedgastriccancerametaanalysis